In the paper, The Shock of Aging: Molecular Chaperones and the Heat Shock Response in Longevity and Aging “ A Mini-Review, in the September 2009 edition of Gerontology (volume 55, pages 550-558), the authors found that molecular chaperone expression declines with aging, setting the stage for more interrogation of the role of molecular chaperone amplification in aging and longevity in human patients.

Jack Barber, Ph.D., Chief Scientific Officer, commented, The authors ™ conclusion of the importance of chaperones in aging coincides with our data indicating the potential of arimoclomol and iroxanadine in age-progressive indications, such as amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig ™s disease, as well as diabetes and its complications, cardiovascular disease, and stroke. The authors speculated that one of the ways to accomplish a pharmacologic stimulation of chaperone synthesis is to activate the transcriptional regulator Heat Shock Factor-1 (HSF-1), and that is exactly the mechanism by which arimoclomol and iroxanadine are thought to work.

CytRx has submitted a revised protocol to the U.S. Food and Drug Administration for its clinical trial with arimoclomol as a treatment for ALS with the expectation that the clinical hold will be lifted in the current quarter.

SOURCE CytRx Corporation